Tanya Parish, PhD
Academic Title: Professor, Department of Pediatrics, University of Washington School of Medicine
Research Center: Center for Global Infectious Disease Research
"As a trained microbiologist, I am motivated to use my scientific knowledge to make a difference in global health. My previous work on the basic biology of Mycobacterium tuberculosis formed an excellent foundation upon which to build a drug discovery team. Using knowledge of vulnerabilities in the bacterial pathogen, we can find tractable and novel drug targets. In addition, a grounding in bacterial physiology allows us to develop relevant screening platforms and to run a battery of experimental assays to select the best chemical series to work on in a drug discovery program. We work collaboratively with a large number of external partners, both industrial and academic, to advance new TB drugs. "
-
Biography
Complete List of Published Work in MyBibliography:
https://www.ncbi.nlm.nih.gov/myncbi/tanya.parish.1/bibliography/public/
My current research is focused in two main areas: (i) understanding the biology of the global pathogen Mycobacterium tuberculosis and (ii) discovering and developing novel drugs for tuberculosis (TB) that are effective at curing drug sensitive and drug resistant tuberculosis.
Previously, I was the Senior Vice President of Drug Discovery at the Infectious Disease Research Institute, where I established a research group focused on tuberculosis drug discovery. Prior to that, I was Professor of Mycobacteriology at Barts and the London School of Medicine and Dentistry (UK), with a research group focused on mycobacterial biology.
Postdoctoral studies, London School of Hygiene & Tropical Medicine, UK
PhD, National Institute for Medical Research, London, UK
BSc in Microbiology and Genetics, University College London, UK
-
Related Pages
-
Our current research is focused in two main areas: (i) understanding the biology of the global pathogen Mycobacterium tuberculosis; and (ii) discovering and developing novel drugs for tuberculosis (TB) that are effective at curing drug sensitive and drug resistant tuberculosis.
-
-
Publications
Manuscripts in Refereed Journals
-
Kumar A, Chettiar S, Brown BS, Early J, Ollinger J, Files M, Bailey MA, Korkegian A, Dennison D, McNeil M, Metz J, Osuma A, Curtin M, Kunzer A, Freiberg G, Bruncko M, Kempf D, Parish TNovel chemical entities inhibiting Mycobacterium tuberculosis growth identified by phenotypic high-throughput screening.
36050506 Scientific reports, 2022 Sep 1 : 12(1)14879 PMCID:PMC9435431 -
Galina L, Hopf FSM, Abbadi BL, Sperotto NDM, Czeczot AM, Duque-Villegas MA, Perello MA, Matter LB, de Souza EV, Parish T, Machado P, Basso LA, Bizarro CVEvaluation of 3-Deoxy-D-Arabino-Heptulosonate 7-Phosphate Synthase (DAHPS) as a Vulnerable Target in Mycobacterium tuberculosis.
35862980 Microbiology spectrum, 2022 Aug 31 : 10(4)e0072822 PMCID:PMC9430761 -
Gold B, Zhang J, Quezada LL, Roberts J, Ling Y, Wood M, Shinwari W, Goullieux L, Roubert C, Fraisse L, Bacqué E, Lagrange S, Filoche-Rommé B, Vieth M, Hipskind PA, Jungheim LN, Aubé J, Scarry SM, McDonald SL, Li K, Perkowski A, Nguyen Q, Dartois V, Zimmerman M, Olsen DB, Young K, Bonnett S, Joerss D, Parish T, Boshoff HI, Arora K, Barry CE 3rd, Guijarro L, Anca S, Rullas J, Rodríguez-Salguero B, Martínez-Martínez MS, Porras-De Francisco E, Cacho M, Barros-Aguirre D, Smith P, Berthel SJ, Nathan C, Bates RHIdentification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions.
35192346 ACS infectious diseases, 2022 Mar 11 : 8(3)557-573 PMCID:PMC8922279 -
Mehdiratta K, Singh S, Sharma S, Bhosale RS, Choudhury R, Masal DP, Manocha A, Dhamale BD, Khan N, Asokachandran V, Sharma P, Ikeh M, Brown AC, Parish T, Ojha AK, Michael JS, Faruq M, Medigeshi GR, Mohanty D, Reddy DS, Natarajan VT, Kamat SS, Gokhale RSKupyaphores are zinc homeostatic metallophores required for colonization of Mycobacterium tuberculosis.
35193957 Proceedings of the National Academy of Sciences of the United States of America, 2022 Feb 22 : 119(8) PMCID:PMC8872721 -
Ahmed S, Manning A, Flint L, Awasthi D, Ovechkina Y, Parish TIdentification of Novel Chemical Scaffolds that Inhibit the Growth of Mycobacterium tuberculosis in Macrophages.
35046812 Frontiers in pharmacology, 2021 : 12790583 PMCID:PMC8762250 -
Hembre E, Early JV, Odingo J, Shelton C, Anoshchenko O, Guzman J, Flint L, Dennison D, McNeil MB, Korkegian A, Ovechkina Y, Ornstein P, Masquelin T, Hipskind PA, Parish TNovel Trifluoromethyl Pyrimidinone Compounds With Activity Against Mycobacterium tuberculosis.
33996738 Frontiers in chemistry, 2021 : 9613349 PMCID:PMC8117417 -
McNeil MB, O'Malley T, Dennison D, Shelton CD, Sunde B, Parish TMultiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors.
33055263 mSphere, 2020 Oct 14 : 5(5) PMCID:PMC7565900 -
Berube BJ, Russell D, Castro L, Choi SR, Narayanasamy P, Parish TNovel MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis and Synergize with Electron Transport Chain Inhibitors.
30962346 Antimicrobial agents and chemotherapy, 2019 June : 63(6) PMCID:PMC6535543 -
Cleghorn LAT, Ray PC, Odingo J, Kumar A, Wescott H, Korkegian A, Masquelin T, Lopez Moure A, Wilson C, Davis S, Huggett M, Turner P, Smith A, Epemolu O, Zuccotto F, Riley J, Scullion P, Shishikura Y, Ferguson L, Rullas J, Guijarro L, Read KD, Green SR, Hipskind P, Parish T, Wyatt PGIdentification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.
29944372 Journal of medicinal chemistry, 2018 Aug 9 : 61(15)6592-6608 PMCID:PMC6089501 -
O'Malley T, Alling T, Early JV, Wescott HA, Kumar A, Moraski GC, Miller MJ, Masquelin T, Hipskind PA, Parish TImidazopyridine Compounds Inhibit Mycobacterial Growth by Depleting ATP Levels.
29632008 Antimicrobial agents and chemotherapy, 2018 June : 62(6) PMCID:PMC5971599 -
Xia Y, Zhou Y, Carter DS, McNeil MB, Choi W, Halladay J, Berry PW, Mao W, Hernandez V, O'Malley T, Korkegian A, Sunde B, Flint L, Woolhiser LK, Scherman MS, Gruppo V, Hastings C, Robertson GT, Ioerger TR, Sacchettini J, Tonge PJ, Lenaerts AJ, Parish T, Alley MDiscovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA.
30456352 Life science alliance, 2018 June : 1(3)e201800025 PMCID:PMC6238539 -
Melief E, Kokoczka R, Files M, Bailey MA, Alling T, Li H, Ahn J, Misquith A, Korkegian A, Roberts D, Sacchettini J, Parish TConstruction of an overexpression library for Mycobacterium tuberculosis.
30197930 Biology methods & protocols, 2018 : 3(1)bpy009 PMCID:PMC6118195 -
Odingo J, Bailey MA, Files M, Early JV, Alling T, Dennison D, Bowman J, Dalai S, Kumar N, Cramer J, Masquelin T, Hipskind PA, Parish TIn Vitro Evaluation of Novel Nitazoxanide Derivatives against Mycobacterium tuberculosis.
30023755 ACS omega, 2017 Sep 30 : 2(9)5873-5890 PMCID:PMC6044914 -
Howell Wescott HA, Roberts DM, Allebach CL, Kokoczka R, Parish TImidazoles Induce Reactive Oxygen Species in Mycobacterium tuberculosis Which Is Not Associated with Cell Death.
28180188 ACS omega, 2017 Jan 31 : 2(1)41-51 PMCID:PMC5286457 -
Chandrasekera NS, Alling T, Bailey MA, Files M, Early JV, Ollinger J, Ovechkina Y, Masquelin T, Desai PV, Cramer JW, Hipskind PA, Odingo JO, Parish TIdentification of Phenoxyalkylbenzimidazoles with Antitubercular Activity.
26295286 Journal of medicinal chemistry, 2015 Sep 24 : 58(18)7273-85
-
Overview
- Research Description
-
My research team is comprised of both biologists and chemists focused on the global infectious disease tuberculosis. We work in two main areas.
First, we are working on discovering new drugs for tuberculosis. TB is the leading cause of death from an infectious disease, with about 1.5 million deaths every year. The current treatment takes more than 6 months and involves multiple drugs. Our work aims to find new drug candidates that can be combined into a novel drug treatment regimen, with the aim of reducing the overall time of treatment. New drugs should also be able to treat drug resistant TB, which is becoming a major problem.
Our research on the more basic science side is focused on understanding how antibiotics function. We focus on what leads to bacterial death when exposed to antibiotics. We also work on the mechanisms of antibiotic resistance. I am especially interested in cell wall biosynthesis and aerobic respiration, as well as other essential cellular processes and gene regulation.